{
  "id": "61f5f0e1882a024a10000014",
  "type": "list",
  "question": "Which factors are inhibited by Abelacimab?",
  "ideal_answer": "Abelacimab is a novel dual inhibitor of Factor XI and Factor XIa.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34297496",
    "http://www.ncbi.nlm.nih.gov/pubmed/34714969"
  ],
  "snippets": [
    {
      "text": "Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the activated FXI.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Fund",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the activa",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) con",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "lic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the activated FXI.OBJECTIVES: To investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single dose intravenous and multiple dose subcutaneous administration of abelacimab in healthy volunteers and patients with atrial fibrillation, respectively.PATIENTS/METHODS: In study ANT-003, healthy volunteers were administered single intravenous d",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation.METHODS: In this open-label, parallel-group trial, we randomly assigned 412 patients who were undergoing total knee arthroplasty to receive one of three regimens of abelacimab (30 mg, 75 mg, or 150 mg) administered postoperatively in a single intravenous dose or to receive 40 mg of enoxaparin administered subcu",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "XI, XIa"
}